OneMedForum New York 2010 Successfully Brings Together Innovators and Investors

By Alex Ludlum

The mid-year conference’s goal was to bring together a promising group of 75 private and microcap companies in 25 different healthcare sectors with a prominent group of European and U.S. institutional investor groups. With over 100 attendees, the enthusiastic response to the OneMedForum New York 2010 illustrates the great appetite for establishing relationships and partnerships between companies and investors to support innovation in healthcare.

“We got contacts and interest from 17 investors, VC, Investment Banks and Angel Groups,” said Gitte Pedersen, CEO of Genomic Expression Inc.

“I believe it was a great forum. Had the chance to talk to some prospective investors; we are currently closing an A round of financing…. but we are about to start our B round and we talked to some investment bankers, some venture capital firms and some angel investors,” said Brian A. Leuthner, President & CEO of Edge Therapeutics.

“This is about the fifth conference that I’ve been to in the last year and I was very impressed. It was very well organized, you could find the different companies and you had breakout rooms to speak to the CEOs. I was very impressed,” said Jordan Savitt, Senior VP at Command Financial.

“I’ve met very interesting companies, the panels are interesting, [and I] met many VCs that we can collaborate with,” said Elka Nir from Giza Venture Capital. “I saw many medical devices companies that seemed to be interesting in the space of cardiology.”

“It’s been a great day for me because I’ve had the chance to meet some talented smart people, who are investors and strategic companies in the industry of orthopedics who are interested in learning more about the technologies and changing patterns and trends…”said Tony Viscogliosi, President of Small Bone Innovations.

“I have been to no less than 4 congress in the last nine months and I have to say that I have gotten more  out of this meeting in two days than I have in the last year and a half for the others. We have gotten 4 contacts that are very promising,” said Roger Kolasinski, President & CEO of NuVue Therapeutics.

Presenting companies included: Abviva, Access Pharmaceuticals, AcuMEMS, AMT, AntriaBio, Arstasis, Axial Biotech, Biomoda, BioNanomatrix, Biovista Inc., The Brain Resources Company, Caleco Pharma Corp., Calibra Medical, Cardiogenesis Corporation, CeQur, CyberHeart Incorporated, Cytochroma Inc., DARA BioSciences, DataPhysics Research, DATATRAK International, DermDx, DiFUSION Technologies Inc., Echo Therapeutics, Edge Therapeutics, Eleison Pharmaceuticals, EpiCept Corporation, Exact Cost, Facet Solutions, Flexible Stenting Solutions, Health Integrated, HiLin Life Products, Insite Medical, LL Tech, Lucid, MacuCLEAR Inc., MedicaSafe, Morris Innovative Research, Myconostica, Nanobiotix, NeoMatrix, NewCardio, NuVue Therapeutics, PAION, PDS Biotechnology Co., PearlDiver, Pressure BioSciences, Principio, Inc., QuantRX Biomedical, RepRegen Ltd., S.E.A. Medical Systems, Silver Bullet Therapeutics, Sound Surgical Technologies LLC, T2 Biosystems, Tagent, Transdel Pharmaceuticals, Trigeminal Solutions, Unity Medical, Urologix, Urovalve, US HIFU LLC, Vasonova, Vaxin, VetCentric, Vyteris Inc. and Xlumena.

The conference also played host to a number of informative panel discussions and workshops addressing issues of significant interest to investors and emerging healthcare companies. Topics covered included capitalizing upon healthcare reform, licensing and intellectual property, capital formation, and commercialization.

Sign up for the SENTINEL to receive more information on these companies and other innovations in health and medicine.